Nirogacestat (dihydrobromide)

Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers[1].

Product Specifications

CAS Number

[1962925-29-6]

Product Name Alternative

PF-3084014 (dihydrobromide) ; PF-03084014 (dihydrobromide)

UNSPSC

12352005

Target

Apoptosis; γ-secretase

Type

Reference compound

Related Pathways

Apoptosis; Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nirogacestat-dihydrobromide.html

Purity

99.9

Solubility

DMSO : 80 mg/mL (ultrasonic)

Smiles

FC1=C2C(CC[C@H](N[C@@H](CCC)C(NC3=CN(C(C)(C)CNCC(C)(C)C)C=N3)=O)C2)=CC(F)=C1.Br.Br

Molecular Formula

C27H43Br2F2N5O

Molecular Weight

651.47

References & Citations

[1]Wei P, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010 Jun;9 (6) :1618-28.